Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularizati… Read more
Xbrane Biopharma AB (XBRANE) - Total Liabilities
Latest total liabilities as of December 2025: Skr110.97 Million SEK
Based on the latest financial reports, Xbrane Biopharma AB (XBRANE) has total liabilities worth Skr110.97 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Xbrane Biopharma AB - Total Liabilities Trend (2012–2025)
This chart illustrates how Xbrane Biopharma AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Xbrane Biopharma AB Competitors by Total Liabilities
The table below lists competitors of Xbrane Biopharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gagasan Nadi Cergas Berhad
KLSE:0206
|
Malaysia | RM434.75 Million |
|
SynCore Biotechnology Co Ltd
TWO:4192
|
Taiwan | NT$14.88 Million |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
USA | $3.72 Million |
|
Elgi Rubber Company Limited
NSE:ELGIRUBCO
|
India | ₹3.76 Billion |
|
Beyond Air Inc
NASDAQ:XAIR
|
USA | $28.49 Million |
|
Iconic Worldwide Bhd
KLSE:9113
|
Malaysia | RM116.25 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Xbrane Biopharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.64 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xbrane Biopharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xbrane Biopharma AB (2012–2025)
The table below shows the annual total liabilities of Xbrane Biopharma AB from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr110.97 Million | -82.49% |
| 2024-12-31 | Skr633.89 Million | +31.47% |
| 2023-12-31 | Skr482.17 Million | +81.52% |
| 2022-12-31 | Skr265.63 Million | +3.48% |
| 2021-12-31 | Skr256.69 Million | +24.57% |
| 2020-12-31 | Skr206.06 Million | +33.27% |
| 2019-12-31 | Skr154.62 Million | -8.95% |
| 2018-12-31 | Skr169.81 Million | +652.89% |
| 2017-12-31 | Skr22.55 Million | +108.67% |
| 2016-12-31 | Skr10.81 Million | -61.15% |
| 2015-12-31 | Skr27.82 Million | +7020.88% |
| 2014-12-31 | Skr390.70K | -22.70% |
| 2013-12-31 | Skr505.44K | -11.15% |
| 2012-12-31 | Skr568.90K | -- |